[The senior deputy editor responds:]
P.G. Brindley shows an admirable appreciation for, ahem, the finer points of editing. The style manual of the Council of Biology Editors (now the Council of Science Editors)
1 argues for a blend of 2 tendencies in the punctuation of abbreviations, namely, the British rejection of that redundant dot after "contraction abbreviations" such as "Dr." and the North American avoidance of clutter in acronyms (AIDS) and initialisms (CIHR). CMAJ's style notes, which take up more pages than anyone could imagine, eschew periods in acronyms and initialisms, as well as in abbreviations appearing in reference lists, but we indulge mild and widely accepted illogicalities such as "Dr." and "Nfld." (when we don't mean NL) and other examples that I cannot place at the end of this sentence without confusing the point. Periods are not used in units of measure, where there is little chance of misreading (6 h, 2.5 mg), and elsewhere are retained on the grounds of both logic and convention (sp., spp.). Suffice it to say we avoid abbreviations where possible. 
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Letters submission process
CMAJ's enhanced letters feature is now the portal for all submissions to our letters column. To prepare a letter, visit www.cmaj.ca and click "Submit a response to this article" in the box near the top right-hand corner of any CMAJ article. All letters will be considered for publication in the print journal.
Letters written in response to an article published in CMAJ are more likely to be accepted for print publication if they are submitted within 2 months of the article's publication date. Letters accepted for print publication are edited for length (usually 250 words) and house style. and does not register nondrug trials. The statements about ClinicalTrials.gov in the memorandum described the situation that existed in 2004, and were provided to explain why at that time CIHR chose to register the trials that it funds with ISRCTN-CCT, rather than with Clinical Trials.gov. These statements were not intended to describe the current state of ClinicalTrials.gov, and I deeply regret the misunderstanding. CIHR endorses ClinicalTrials.gov as a high-quality public trials registry.
Since I wrote the memorandum in early September, the ISRCTN-CCT registry has acquired not-for-profit status, and now complies with the ICMJE requirements. CIHR will therefore continue to register the trials that it funds with the ISRCTN-CCT. CIHR is also working with the World Health Organization to establish a global system for trials registration, which will link the various public registries to improve access and reduce duplication.
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